Our findings are in accordance with recent reports which demonstrated that STAT5 accounts for the resistance against Gleevec and inhibition of STAT5 can effectively decrease survival of CML cells resistant to tyrosine kinase inhibitors [52,53]. This evidence concerns the gene STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive.